Table 6.
Overall survival according to MSKCC risk group and systemic therapy
| Number of patients
|
Median OS (months) with 95% CI | Hazard ratio with 95% CI | P-value | ||
|---|---|---|---|---|---|
| Died | Total | ||||
| Entire cohort | 91 | 111 | 17 (13–22) | / | / |
| MSKCC risk group: favorable | |||||
| Systemic therapy | 0.0009 | ||||
| Targeted therapy | 12 | 18 | 22 (17–44) | 0.13 (0.03–0.53) | |
| Immunotherapy | 4 | 4 | 12 (4–15) | ||
| MSKCC risk group: intermediate and poor | |||||
| Systemic therapy | 0.04 | ||||
| Targeted therapy | 45 | 56 | 15 (10–24) | 0.55 (0.31–0.98) | |
| Immunotherapy | 16 | 16 | 10 (4–16) | ||
Abbreviations: CI, confidence interval; MSKCC, Memorial Sloan-Kettering Cancer Center; OS, overall survival.